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Available online 30 April 2019Background:Newborn bloodspot screening (NBS) for cystic fibrosis (CF) is a well-established public health strat-
egy with international standards. A European survey demonstrated considerable variability in approach to deliv-
ering a positive NBS result.We used amixedmethods approach to explore healthcare systems and beliefs around
this process.
Methods:We used semi-structured interviews and online questionnaires with a purposive, international sample
of health professionals involved in communicating positive NBS results to parents. Datawere analysed using the-
matic analysis and Qualtrics Survey Software.
Results: In total, 63 healthcare professionals were approached; 25 interviews were conducted with delegates at
the 2017 ECFS conference, 4 online questionnaires were subsequently completed by participants in the EU, 1
from Australia and 33 from the US. Methods used to communicate positive NBS results to families varied consid-
erably. This influenced the quality and quantity of information providedwhich had the potential to heighten anx-
iety and affect timely diagnostic testing. Participants identified positive practices including systems to improve
the timeliness of screening and processing of results, as well as areas for improvement. Respondents stated
that knowledge of CF and familiarity with the family were both important when deciding who should commu-
nicate positive NBS results.
Conclusions:Guidance and practice regarding communication of positive NBS results for CF to families varies con-
siderably internationally. Further research is needed to ensure information received is accurate, up-to-date and
from the most appropriate person. Also, that all children are followed up in a timely manner to minimise poten-
tial negative outcomes for the child and family.




The introduction of newborn bloodspot screening (NBS)
programmes internationally over the last 50 years for a range of
inherited conditions has been an important public health initiative
[1,2]. Screening for cystic fibrosis (CF) has been incorporated into
most of these programmes. The rationale for NBS for CF is well
established [3] however, there continues to be challenges in terms of, Cystic Fibrosis; CFSPID, Cystic
pean Union; ECFS, European CF
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f European Cystic Fibrosis Society.its implementation [4]. One of these challenges relates to the way posi-
tive NBS for CF are communicated to families. The clinical spectrum in
screen positive cases varies enormously and consequently the message
to parents needs to be accurately presented for a range of outcomes.
Communication of positive NBS results is a challenging task which re-
quires preparation and evidence to minimise potentially harmful nega-
tive sequelae [5–9].
The consent process for NBS varies internationally. In the UK, NBS is
offered on a voluntary basis. Parents are required to provide informed
consent (but not written) and ‘opt in’ to the screening programme.
This is different to most of the United States (US) and Canada where
an ‘opt out’ approach is taken. Recent findings from a review of the ex-
pansion and performance of national newborn screening programmes
for cystic fibrosis in Europe [10] found that written informed consent
was mandatory in six (38%) countries. The consent process will influ-
ence parents' knowledge and expectations regarding the communica-
tion of positive NBS results.
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are communicated to families. In the US, qualitative interviews with
28 parents following their child's positive NBS result for CF demon-
strated communication of the positive NBS result resulted in parental
uncertainty and emotional distress. This was influenced by the ap-
proach to informing parents of the result with face-to-face communica-
tion (as opposed to use of the telephone) and the physician having time
and knowledge to explain the results in detail being preferable [11].
These findings were supported by another study which consisted of
telephone interviews with 270 parents following communication of
carrier status after NBS for CF and sickle cell disease (SCD). The findings
indicated that content and knowledge of the person imparting the re-
sult, was important in terms of the parental experience of the process
[12]. A more recent study in Switzerland exploring parents' perspective
of NBS for CF found that parental dissatisfaction with the communica-
tion of the NBS result was associated with poor information provision
about the screening result and the actual disease, again demonstrating
the importance of ensuring the information is delivered by someone
who is well-informed [13].
A study of NBS in Europe [10] reported 17 national programmes, 4
countries with regional programmes and 25 countries not screening
for CF. The screening algorithms in these countries differed; further de-
tails of the individual algorithms are described in the paper [10]. Briefly,
all programmes used measurement of immunoreactive trypsinogen
(IRT) for first tier testing. However, second tier testing differed consid-
erably with four programme using repeat IRT, two programmes using
pancreatitis-associated protein, ten programmes using DNA analysis
with panel sizes ranging from 4 to 644 mutations. Four used further
IRT testing at day 21 for infants with one mutation recognised and
three programmes used extended gene sequencing for infants with
one recognised mutation. Ten used a “safety net” with infants with a
high IRT but no mutation recognised being referred for further testing.
National programmeswere also found to employ different protocols, re-
garding processes used to communicate positive NBS results to families.
A positive NBS result was most often reported by the CF centre, and in
most cases, by telephone. It was also found that the result may be re-
ported to the family by a CF Physician, a specialist CF nurse, a commu-
nity Nurse or a Family Doctor. Two countries reported the result being
communicated to the family directly by the NBS laboratory. The details
of the different approaches, and the health service beliefs underpinning
these approaches have not been explored.We aimed to explore interna-
tional healthcare systems and beliefs around the NBS process.
We explored the experience of delivering positive NBS results to
families to examine existing practices in more detail. We approached
countries with established NBS programmes.
2. Methods
This was a mixed methods study using semi-structured interviews
and online questionnaires with a purposive, international sample of
health professionals involved in communicating positive NBS results
to parents. For the purposes of this study, a positive NBS result referred
to the initial result prior to second tier testing [10]. Ethical approval was
granted by the Research Ethics Committee at City, University of London
(Staff/16-17/25).
Members of the European CF Society (ECFS) Neonatal Screening
Working Group (NSWG) were contacted via email prior to the ECFS
Conference in June 2017 (n = circa400, it is not known how many of
these met the eligibility criteria). Information about the proposed
study was included as well as contact details of the research team.
Members of the NSWG were considered eligible and advised to contact
the study team to discuss inclusion in the study if they were involved in
communicating positive NBS results to families, attending the ECFS con-
ference and willing to be interviewed.
Members of the NSWG who responded to the email and expressed
an interest in the proposed study were sent an invitation via DoodlePoll which allowed them to select dates and times during the 2017
ECFS conference that would be convenient for them to participate in a
face-to-face interview. Once the Doodle Poll had been completed by
all interested parties, each potential participant was sent a final invita-
tion via email including a date and time to be interviewed at the ECFS
conference.
Semi-structured interviews were conducted at the 2017 ECFS con-
ference in a separate room in the conference venue. Prior to the inter-
view taking place, written, informed consent was obtained from study
participants. Interview prompts were derived from the literature and
agreed by the research team. Interviews were audio-recorded and tran-
scribed verbatim.
Prior to and following the 2017 ECFS conference, members of the
NSWG who were not at the conference, contacted the research team
and expressed an interest in being involved in the study. Therefore,
the interview prompts were developed into an online questionnaire
using Qualtrics Survey Software. This was circulated to members of
theNSWGwhowere not present at the 2017 ECFS conference. To gather
data from theUS, an adapted version of the online surveywas circulated
to all US Centre Directors (n= 50).
Similar questions were used for the interview guide and the ques-
tionnaire. Each started with questions aimed at gathering demographic
data such as; country of work, job title, number of years involved in the
NBSprocess. Thiswas followed by questions related to their role in com-
munication of positive NBS results and the NBS programme in their
country including the age at which the bloodspot is taken, who takes
the bloodspot, the NBS algorithm used, consent procedures and what
is considered a positiveNBS result. Next participantswere asked specific
questions related to how results are communicated to parents such as
timing, people involved and the process and content of the communica-
tion. Also, what second tier testing is undertaken, how and by whom
and how the results of the second tier testing are communicated to
the family? Following this, participants were asked their opinions re-
garding these processes such aswho they thought themost appropriate
person was to communicate the result, how this should be done, what
they thought worked well about their NBS programme and any im-
provements they might like to see.
2.1. Data analysis
Quantitative (demographic) data from the interviews and question-
naires were analysed initially using simple descriptive statistics and are
presented in Figs. 1–3. Following this, qualitative data from the semi-
structured interviews and the open-ended questions in the online ques-
tionnaire were analysed thematically [14]. This process consisted of six
phases; familiarisationwith the data, generating initial codes, searching
for themes, reviewing the themes, defining and naming the themes and
producing the report.
3. Results
Twenty-five interviews were conducted at the 2017 ECFS confer-
ence lasting on average 30min (range 15–47min). Four questionnaires
were completed by participants in the EU, 1 from Australia and 33 from
the US (see Fig. 1). As responses from Australia and New Zealand were
low, these were grouped with the EU responses due to similarities in
health care structure and organisation. Data from the US were analysed
separately. Health care professionals involved in the study comprised
centre directors, doctors, nurses, professors, research scientists, genetic
counsellors and NBS co-ordinators (see Fig. 2).
Responses indicated there are differences in terms ofwho communi-
cates the initial positive NBS result to families. In the US, this was pri-
marily the Primary Care Physician (PCP) but in the EU/Australia/New
Zealand, this varied widely and included a range of professionals (see
Fig. 3).
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Fig. 1. Number of interviews and questionnaires conducted in each group.
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(ii) challenges and (iii) areas for improvement each of which contained
subthemes.Managing communication of the positive NBS resultwas in-
fluenced by structure, provision and availability of services and this in-
fluenced the care families were perceived to receive.3.1. Positive practices
Many positive practices were identified by participants. These have
been divided into the following subthemes, communication and co-
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Fig. 2. Health care professiona3.1.1. Communication and co-ordination
Several respondents from the US highlighted effective communica-
tion between the screening laboratory, the PCP and the CF centre as a
positive aspect of their NBS programme and commented on how this
had improved over time. This enabled professionals to provide appro-
priate information to families during theprocess from screening to diag-
nosis. This also made respondents feel that they were unlikely to have
any missed cases.
Similar responses were obtained from health professionals from the
EU/Australia/NewZealand. However, often thiswas a perception of how
important good communication is and the detrimental effect of poor
communication practices.stralia / New Zealand







US EU / Australia / New Zealand
Fig. 3. Professional who communicates the initial positive NBS result to families.
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off on the bad foot that they [the parents] are influenced very lengthily.”
Germany.
In the EU/Australia/New Zealand, positive communication practices
more commonly referred to communication with the family and co-
ordination of care after the family had been seen in the CF clinic as op-
posed to communication of the initial positive NBS result (e.g.
Germany).
“Starting that day quickly from the result of the sweat test, we have a
very structured plan that wewill talk about once they have a positive diag-
nosis, how the admission works, what they will learn during the admission,
that we have an on call service that they call and we really encourage that
and I think that from that time on they do feel that you know there is some-
one regardless of what happens that they can address their question to.”
Germany.
In the EU/Australia/New Zealand, there was an appreciation of the
importance of good communication at all stages when communicating
positive NBS results from the laboratory to parents. This was demon-
strated in communication between health professionals and families
once the child and family had been referred to and/or seen at the CF
clinic. However, it was often felt that the initial communication of the
positive results could be performed better.
3.1.2. Timeliness
Ensuring that children and their families were seen in a timely man-
ner after receiving the initial positive NBS result was deemed very im-
portant. Many respondents from the US commented on this in relation
to children being seen quickly in the CF clinic following the positive
screening result.
“Most patients seen before 2 weeks of age.” US.
“Timeliness in specimen collection, shipping, reporting and follow-up”
US.
Similarly, respondents from the EU/Australia/New Zealand
commented on the importance of timeliness in terms of communicating
with the families.
“..it's good that we get onto it quickly, it's good that the midwife and the
family know to contact us almost immediately…and I think it's good that
we can get them in within 24 hours.” New Zealand.
“What I thinkworks well is thatwe do not leave toomuch time between
the initial message that screening is positive and the first visit in thehospital, so I think it's very important that you don't leave too much time
between that. So, because otherwise parents have too much time to think,
and to be worried, and for uncertainty.” Netherlands.
Many respondents from the US commented on the timeliness of the
sweat test and availability of results.
“Sweat test results [are available] the same day.” US.
“Time to sweat test and time to diagnosis when family can be found and
has PCP goes very well.” US.
Timeliness of the sweat test was variable in the EU/Australia/New
Zealand. In Italy and Germany for instance the result of the sweat test
is available the same day, indeed in Germany it is almost instant.
“…you get the results if you do it immediately after the sweat was col-
lected and you have, five minutes later” Germany.
In some countries, the sweat test is done separately after the parents
have been told the child has a positive NBS result but before they were
seen by the CF team. Therefore, the intention is for the results to be
available when the child is seen for the first time by the CF team. In
other places such as the UK and New Zealand, the results of the sweat
test were commonly not available the same day, and were then given
to parents over the telephone the following day. This was commonly
due to the availability of services to undertake and report the sweat test.3.1.3. Multi-professional team
Internationally, the importance of involvement of members of the
multi-professional team and effective teamwork in the care of children
with CF and their families after they had received the initial positive NBS
result was highlighted. However, there was variations in terms of when
differentmembers of the team became involved and the composition of
the team. In most instances the CF doctor and CF nurse were the first
members of the teamwhowere involved with the family. In the US, in-
volvement of a genetic counsellor early in in the families' journey was
viewed favourably.
“The presence of a genetic counsellor has been reported to be very help-
ful by families as they are professionals who are used to provision of infor-
mation at a variety of educational levels to families under stress. The use of
the genetic counsellor while the sweat test is going on provides a distraction
from “going to the bad places” while also providing reassurance about the
relatively low risk of their child having CF and the importance of early de-
tection should the test be positive” US.
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Australia/New Zealand was rare and in Italy this was viewed less
favourably.
“The problem is that we don't have a geneticist inside the CF centre.”
Italy.
Early involvement of members of the multi-professional team was
deemed valuable by all while acknowledging the importance of not
overwhelming the family.
“We try to call the whole team, or different members from the whole
team… if you are alone it is also not good, but if we are two or sometimes
three, then that is very helpful…. Most of the time we are only two, but this
is already okay because on the other side you have also two people. You
know, if you would come with five this is probably scary.” Germany.
3.2. Challenges
Several challenges of the NBS processwere identified and have been
grouped into three subthemes; sweat test, professional roles, and ge-
netic mutations.
3.2.1. Sweat test
While some respondents in the US commented on the timeliness of
sweat testing and receiving the results, others raised concerns about the
sweat testing process. One of these appeared to be with the way sweat
testing is recorded particularly for patients where only one mutation is
identified.
“We have delays if there is a positive NBS but 1 mutation because we
don't have a good way to track if/when the sweat tests are ordered/sched-
uled” US.
Another issue identified was the timing and success of performing a
successful sweat test.Many respondents commented on beingunable to
get a definitive result due to the quantity of sweat collected being insuf-
ficient presumably due to the weight of the child.
“I wish we could perform the sweat test sooner after the positive screen,
but the high QNS [quantity not sufficient] rate necessitates waiting for 2–4
weeks before performing the confirmatory test” US.
Similarly, in the EU/Australia/New Zealand, issues related to the
timeliness and success of sweat testing were also raised. In Turkey and
Germany, parents are expected to arrange the sweat test after they
had been informed that their child has a positive NBS result. In
Germany, this was due to legal requirements that meant the CF centre
could not be sent patient details. This raised concerns for clinicians in
terms of ensuring that babies who have a positive NBS result are
followed up in terms of the sweat test and being seen by the CF team
in a timely manner.
“I think what's very difficult is the tracking. Who comes at which time?
Because, you know, if the parent stays at home, we have no information. In
the legal way [of] how things should happen.” Germany.
“It decrease their urgency to coming to see us becausemany families re-
ject to come and so there are delays in that diagnosis… they say ok the baby
is fine, there is no need to come because sometimes they come to the hospi-
tal and they couldn't find out and then they say ok he or she is not ill”
Turkey.
This can have serious consequences
“I learned that the family rejected to come to the university…He had a
positive screening test but unfortunately the baby died. The family, I
learned, rejected to come to the university for a sweat chloride test…I didn't
learn about that positivity until that patient had died.” Turkey.
3.2.2. Professional roles
Professional roles did not appear to be an issue in theUS perhaps due
to the fact that it was most commonly the PCP who communicated the
initial positive NBS result to families. However, in some countries in the
EU/Australia/New Zealand there are issues related to who is seen to
‘own’ the screening result. In Germany, it is usual practice for the posi-
tive screening result to be communicated back to the maternity wardwere the screening was performed. Indeed, the maternity ward are
not allowed by law, to contact the CF centre and give them personal
data about the patient. Therefore, the positive NBS results is given by
an obstetrician (Germany) or a General Practitioner (Turkey) who is
not perceived to have expert knowledge of CF which impacts on the
message given to parents:
“…most of them cannot get any information from the GP and theywere
so curious and some were just very anxious… most of them were not in-
formed by the GP about CF.” Turkey.
This was also the case in New Zealand where midwives were re-
sponsible for the care of mothers when the result of NBS became avail-
able and so they were considered to be best placed to communicate the
positive NBS result.
“…themidwife then delivers the information to the family she, not owns
the family but she is the one that has been responsible for the care to that
point so…she delivers the information to the family… it's sort of almost
who owns the information in the healthcare at that point.” New Zealand.
This is also the case in the Netherlands:
“Officially, we are not allowed to contact the parents, because we do not
have a relationship with them yet…the GP has the relationship with the
family.” Netherlands.
Conversely, in the UK, there were issues in terms of people who
were not CF specialists feeling it was not their job to deliver the initial
positive NBS result.
“Some [health professionals] say ‘well that's not really our job to do’.
Well? Okay, well, whose job is it?” UK.
Perceptions of the roles of different health professionals in terms of
both job description and information ownership therefore also compli-
cates communication of positive NBS results.
3.2.3. Genetic mutations
The choice of DNA panel was mentioned by some states in America
as having implications in terms of identification of those patients con-
sidered to have CF or CF screen positive, inconclusive diagnosis
(CFSPID).
“Our state has elected to gowith a very narrow panel of 23 genes. This is
not commensurate with our diverse and ethnic population.” US.
In someparts of Turkey, because of thewide range of CFmutations, it
has not been possible to find a cost-effective DNA panel and therefore
commonly DNA analysis is only undertaken after diagnosis i.e. after a
positive sweat test. However, in other areas of Turkey, the high rates
of consanguinity mean if relevant, the child may undergo advanced ge-
netic analysis.
Issues were also raised in terms of the importance placed on the
identified mutations during the screening process. One respondent in
the UK explained the difficult position the CF expert can be put in
when giving a screening rather than diagnostic result i.e. prior to second
tier testing particularly if they are aware of the genetic mutations.
“…it felt quite uncomfortable, in some situationswe knew the diagnosis,
but we weren't there to give the diagnosis, and we were then saying ‘you
need to come to the hospital this afternoon’, we had a few patients say to
us…‘well you knew this result, and you were sat in our house this morning,
but you-‘. They kind of get why I suppose you didn't tell them…we started
getting embroiled in lots of conversations about CF, and what it means,
without them actually having a full on diagnosis and that felt uncomfort-
able …” UK.
There are also legal considerations with respect to the DNA compo-
nent of NBS. In Germany, mutations will only be released to the physi-
cian upon request and after the child has received a positive sweat
test. Therefore, carriers will not be identified or told about their status
as carrier screening is not allowed but parents should be made aware
of this when theNBS is performed. Similarly, in Norway, due to law, car-
rier results are not reported. Additionally, in Germany,midwives are not
allowed to perform the bloodspot for CF because it identifies genetic in-
formation and in German law only doctors can give information about
genetic diseases. Therefore, those children who are born outside of
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on time.
3.3. Areas for improvement
Respondents identified many areas for improvement which were
encompassed in the subthemes; provision of services and information
giving.
3.3.1. Provision of services
In the US, in some states, geography hampered the perceived effi-
cacy of the NBS programme.
“We are really challenged by geography. The nearest other CF Center to
us is a 5 hour drive away. We have some patients who drive 6+ hours to
come see us.” US.
Thiswas also seen as an issue in someparts of Turkeywhere families
could have a considerable distance to travel which could even involve
anovernight stay in order to obtain the sweat test. Thiswas felt to be an-
other barrier to parents ensuring their child is followed up following a
positive NBS result.
3.3.2. Information giving
Agreement in terms of the right person to communicate the initial
positive NBS result to families was a contentious issue. Communication
between the screening laboratory, the PCP and the CF centre was
viewed positively in the US. However, many respondents in the US
were concerned with the information parents received from the PCP
who was the most common person to communicate the initial positive
NBS result to parents.
“Some PCP's do not do as recommended - some call families with results
and give vague if not outright incorrect information.” US.
“Education for PCP so that they are more knowledgeable and improve
communication with parents” US.
Respondents commented that when incorrect information was
given by the PCP during the initial communication, this created compli-
cations later on in terms of ensuring parents had a good understanding
of CF and its treatment. This was also reflected in Turkey where misin-
formation from the GP could impact on parents seeking confirmatory
testing.
“I don't know what they [GP] tell to patients, but I know some bad
stories about the knowledge taught by GPs. Sometimes they can say that
it's a very bad disease, and you can't do anything to your baby, it's a very
bad disease. Sometimes, they [the parents] don't want to come to the Uni-
versity in that case. I think the education of the GPs is very important.”
Turkey.
This was also reflected in responses from the UK where more com-
monly, the positive NBS result is given by a member of the CF team
(CF nurse or less commonly the CF doctor). Respondents generally
expressed a preference to deal with the initial communication for fear
of the GP or health visitor not being well equipped in terms of their
knowledge of CF to deliver accurate information to the family.
“Well [other health professionals] don't know a lot about CF I don't think
and I it's not really very fair on them to ask them to do that…they don't
have a background of CF…sometimes you get asked a lot of questions and
obviously, they would keep saying I don't know I don't know which I
don't think would be particularly good for families…I don't think it's appro-
priate really it needs to be somebody with a background of CF.” UK.
The importance of the most appropriate professional giving the
news to families was also recognised by respondents in New Zealand.
“…given the number of midwives and children its very common that
this will be the first child that she delivers this information to and she
won't know much about cystic fibrosis and so the conversation [with the
CF nurse] before she talks to the family is very important it gives her confi-
dence and she kind of runs throughwhat she is going to say or if there is any
questions. It also means that if the family asks something that she doesn't
know that is unexpected she doesn't feel at a loose end” New Zealand.However, it was also felt that the person communicating the initial
positive NBS result should also be known to the family.
“…the midwife is the first person to contact them because they don't
know us, you can't call somebody you haven't seen in your life…The mid-
wife, or the person who is looking after the parents the whole time would
call the parents and give the results… itmakesmuchmore sense if someone
who knows the people actually tells them the results.” New Zealand.
Currently in Germany, the screening laboratory informs the birth
clinic, the birth clinic informs the parents, and the parents have to orga-
nise their diagnostic confirmation themselves. However, this was not
seen to be ideal by the CF health professionals interviewed.
“I personally think it's the communication from the CF centre [that] is
more important, because these are the persons you want to work together
with for the next 18 years, or even longer, whatever you build up as a con-
nection to the family, if you are the first one to discuss itwith the family, you
have some additional advantage. The maternal department… they're not
well trained to do this type of communication, and to be able to answer
every question related to cystic fibrosis.” Germany.
The importance of both parents being presentwhen communicating
the initial positive NBS was acknowledged by most participants. How-
ever, the logistics of ensuring this happened was seen as a challenge.
“I tell them [the parents] they can go on the speakerphone sowe can talk.
Everyone can hear it. But usually when you call them when they're two
weeks, inDenmark, theDadhas twoweeks paternity leave, and thenheusu-
ally goes back to work. So…only the mother has been at home”. Denmark.
“…if there's a dad, partner or husband, they've probably just gone back
to work after their paternity leave. It's, you know, bad timing. But, [we] are
very mindful of that and they'll quite often, the mums will call a grandma,
or a partner or husband, or a friend to come round with them.” UK.
In Europe, the general consensus was that parents should be de-
terred from looking at the internet to find out more about CF prior to
being seen in the CF Centre.
“…don't go on the internet and look everything up, because you'll see
the worst cases.” Netherlands.
“So I would actually have the maternity ward communicate that they
shouldn't look…at the internet” Germany.
“We tell them [health visitors] to suggest that families don't get on the
internet…but of course most of them do…” UK.
There was wide variation regarding whether the genetic mutations
should be disclosed to the parents during the initial communication of
the positive NBS result. In some parts of Italy, this information is pro-
vided in writing to the parents before they are seen in the CF centre.
In the UK, the Netherlands and Denmark, some respondents stated
that if they knew the mutations, they would disclose them to parents
during the initial conversation. However, this seemed to be based on
personal choice rather than relying on relevant protocols.
“So I know the guidance is not to tell them the genetics…but I do say…
they've found two mutations” UK.
“So, if the baby is, for example, homozygous for 508, they [the laboratory]
will report that. Forus, that is diagnostic. I knowthat it's a screening tool, but
our experience is, we've taken it as diagnostic and, therefore, wewill deliver
thatresult asdiagnostic… I think that'smorallywrong[tonot tell theparents
their child has CF] because the baby has got cystic fibrosis...” UK.
“We've tended to give a diagnosis based on the mutations and the IRTs,
so the sweat test hasn't been a make-or-break thing.” UK.
In Turkey, the diagnosis was given following a variety of outcomes:
“Some of our patients get the diagnosis with only the genetic-test posi-
tivity. Some of them, both genetic-test positivity and sweat chloride test
positivity. Some of them have only sweat chloride test positivity.” Turkey.
In other countries such as New Zealand, Switzerland and Serbia,
these would not be available until after the sweat test and in Germany
only if requested. In Italy, the Czech Republic and Norway, even if the
mutations were known, they would not be discussed with the parents
until after the sweat test.
To summarise, thematic analysis led to the identification of
3 main themes regarding communication of positive NBS results to
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ment. Positive practices included interagency communication when
processing the NBS result, the timeliness of processing the result and
communicating the positive NBS to the family and involvement of the
multi-professional team early in the families' journey. Challenges
included obtaining the sweat test, the role of different health profes-
sionals in the NBS process and communication of genetic information
to families. Areas for improvement included provision of services both
in terms of geography and availability of services such as sweat testing
and information giving. The latter highlighted the importance of
efficient, accurate and reliable information being given the family by a
health professional with knowledge of the relevant NBS algorithm as
well as condition specific knowledge.
4. Discussion
This piece of work confirms the findings of extreme variants across
the globe in the delivery of positive NBS results. This variation was
due to many factors including geographical/logistical, legal, financial
and cultural constraints. Processing and communicating positive NBS
results for CF well, is challenging and requires training and experience.
We have identified three key elements of the NBS process for CF;
(i) interagency communication between the laboratory and relevant
health professionals such as PCPs or the CF team, (ii) the first interface
with the family and (iii) the diagnostic process.
A key element is how the positive NBS result is processed. For most
countries, interagency communication and co-ordination between the
laboratory and relevant health professionals such as the PCP or the CF
team was viewed as a positive aspect of the NBS programme. The im-
portance of this being done efficiently and reliably was acknowledged.
The first interface with the family was often viewed less favourably
than interagency communication. There was a lack of consensus in
terms of who is the most appropriate person to inform the family
with responses indicating knowledge and familiarity are both consid-
ered important. The importance of knowledge is consistent with previ-
ous research [11–13] but familiarity has not been considered previously.
In the US, communication with families is most commonly under-
taken by the PCP. However, the findings of this study support the find-
ings of previous work [11,12] and suggest that PCPs continue to be
inadequately prepared to undertake this role. In the EU/Australia/New
Zealand, a range of professionals are responsible for communicating
the positive newborn screening result to families. Provision of complete
and accurate information was considered to be associated with reduced
parental anxiety and better decisionmaking regarding seeking diagnos-
tic testing and support from the CF team. In some countries in Europe
such as Turkey, regulations regarding who ‘owns’ the information
about the positive NBS result and therefore who communicated the re-
sult to the family had the potential to influence their perceptions of the
urgency and/or necessity for their child to be followed up by the CF
team. The key element is that the information parents received during
the initial communication of the positive NBS result is accurate and up
to date. There may be a tension between trying to achieve familiarity
i.e. someone the family knows and someone that has the knowledge.
However, someone who only communicates positive NBS results once
or twice in their career is going to find this challenging and it is perhaps
better to have someone who is not known to the family but does know
about the condition and is therefore able to alleviate parental anxiety.
These findings are commensurate with findings of studies that have
explored communication of positive NBS results for other conditions in-
cluded in the NBS Programme. For instance, a study in the US which fo-
cussed on communication of carrier status for CF and sickle cell disease
found that content and knowledge of the person imparting the result,
was vital in terms of parental experience of the process [12]. Similarly,
a study in the US which explored parental experiences of receiving a
positive NBS result for a metabolic condition suggested the methods
used to communicate the NBS result and the condition specificknowledge of the individual imparting the result influenced parental
dissatisfaction, anxiety and distress. Results delivered over the tele-
phone, by staff not known to the families or without condition specific
knowledge were viewed less favourably [17]. More recently, a study
with parents who had received a positive NBS result for a metabolic
condition included in the expanded NBS programme in the UK sug-
gested that first contact between the parent and the health professional
relay the screening result left a strong lastingmemory with parents and
that the initial contact need to provide ‘the right amount of information’
but the quantity and content was difficult to define [18]. These findings
support those of the present study and suggest that the need for the ini-
tial communication to be undertaken by someone with condition spe-
cific knowledge is not unique to CF.
The situation in Germany is unique and of concern to participants in
this study from that country. The system for processing a positive NBS
result complies well with the ethical principle of autonomy, as the fam-
ily are able to decide the clinical care pathway, but it is clear that
healthcare workers in Germany feel this places families at a significant
risk of receiving inaccurate early information and inappropriate early
CF care. Both of these would be counter to the ethical principles of be-
neficence (doing good) and non-maleficence (avoiding unnecessary
harm). This system is not imposed because of a lack of health service re-
source (as is the case in some other countries). It is clear that processing
a positive result through the well-established CF centres would be pos-
sible and that this State mandated process represents the impact of cul-
tural beliefs on a health system. Some reports suggest similar pathways
occur in some countries and states in the US, but the families appear to
receive clearer direction in those cases.
In terms of the diagnostic process, respondents indicated differences
in terms of the structure and involvement of the multi-professional
team. The US viewed the inclusion of a genetic counsellor from the out-
set as important. However, in the EU/Australia/New Zealand, there was
a distinct view that genetic counselling should not be embedded in the
CF team but should be separate to allow families the opportunity to talk
openly about issues such as future reproductive decisions while not
feeling compromised or embarrassed.
Timeliness in terms of the period between screening and diagnosis
was viewed positively by most respondents. However difficulties with
the sweat testing process were expressed. These included families not
understanding the importance or need for the sweat test, difficulties
in accessing services due to geography as well as difficulties obtaining
sufficient sweat to provide a definitive result. Worldwide, the sweat
test remains a key and important part of the diagnostic process and
age-related changes in sweat chloride should be taken into account
[15,16]. Howeverwhen a sweat test result is unavailable, a presumptive
diagnosis should be made and treatment should not be delayed. In the
US, many respondents acknowledged the difficulty of obtaining a
sweat test in infants who were too small at the initial appointment
with the CF team.
In terms of diagnosis, as mentioned above, sweat chloride concen-
tration is considered the gold standard [15,16]. However, many respon-
dents stated that if two CF causing variants (according to CFTR2) were
identified during the screening process, they would consider this diag-
nostic and would often communicate this to the family before sweat
testing had been attempted. Respondents provided a range of reasons
for doing this including,moral judgement in terms of notwanting to de-
ceive families or not wanting families to feel later on that they had been
deceived, reassurance from personal experience that the screening re-
sults have never been inaccurate as well professional judgement
based on the screening result and clinical assessment providing enough
evidence that the child has CF.
These findings have implications for future research, practice and
education. The most appropriate person to inform parents of their
child's initial positive NBS result needs to be determined from aparental
and practical perspective. The quantity and content of information pro-
vided to parents when they're informed of their child's positive
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tiatives and ensure communication is reliable and reproducible. The
findings of this study reiterate the need for the person informing the
family of their child's positive NBS result to completely understand
the NBS algorithm used and themeaning of the screening result. Practi-
tioners must provide a coherent message when genetic information
and/or clinical findings are indicative of a diagnosis of CF but when a
sweat test is either unavailable or unachievable to ensure practice is
consistent and care for families is equitable.
In terms of the study limitations it is important to consider serval
factors that may have biased both data collection and study findings in
the present study. These included selection bias; participants who are
members of the ECFS NSWG, and who attended the ECFS meeting,
may not be representative of the wider groups who care for children
with CF, or communicate results of CF NBS. Equally, there may have
been a bias in terms of who chose to respond to the online survey. The
response ratesmay have also limited the generalisability of thefindings.
Observer bias should also be acknowledged. All study authors have
prior knowledge, experience and a particular interest in CF NBS which
may have influenced data collection and interpretation of study find-
ings. To mitigate against this, interviewing and data analysis were un-
dertaken by an experienced researcher. Respondents to this study
were not always the person responsible for communication of the pos-
itive NBS result to parents. This means that these opinions may not ac-
curately represent the views of those undertaking the initial
communication.
In conclusion, guidance and practice regarding communication of
positive NBS results for CF to families varies considerably internation-
ally. The key finding of this study is that information provided to the
familymust be accurate, up-to-date and provided by themost appropri-
ate person. Whatever process is established must ensure this happens
consistently and in a timely manner.
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